Seeking Alpha
 

Bio-Reference Laboratories, Inc. (BRLI)

- NASDAQ
  • Tue, Jun. 9, 5:37 PM
    | Tue, Jun. 9, 5:37 PM | 7 Comments
  • Thu, Jun. 4, 9:14 AM
    | Thu, Jun. 4, 9:14 AM | 3 Comments
  • Thu, Jun. 4, 8:24 AM
    • In a all-stock deal, OPKO Health (NYSE:OPK) acquires Bio-Reference Laboratories (NASDAQ:BRLI) for $52.58 per share or ~$1.47B. BRLI shareholders will receive 2.75 shares of OPK for each BRLI share.
    • OPKO intends to leverage BRLI's commercial organization to enhance sales of its diagnostic tests, including 4Kscore, a blood test for prostate cancer.
    • OPK is down 7% premarket on increased volume. BRLI is up 43% premarket on robust volume.
    | Thu, Jun. 4, 8:24 AM | 13 Comments
  • Aug. 28, 2014, 12:46 PM
    | Aug. 28, 2014, 12:46 PM | Comment!
  • Aug. 26, 2014, 5:35 PM
    | Aug. 26, 2014, 5:35 PM | Comment!
  • Jun. 5, 2014, 3:53 PM
    • Shares of BioReference Laboratories (BRLI +20.6%) jump on a 5x surge in volume in response to its fiscal Q2 earnings report.
    • Net revenues: $201.4M (+14.1%); operating income: $18.9M (-8.7%); net income: $10.3M (-8.8%); EPS: $0.37 (-9.8%); cash & equiv: $24.5M (+36.1%).
    • Revenue/patient: $84.18 (-0.9%).
    | Jun. 5, 2014, 3:53 PM | Comment!
  • Jun. 5, 2014, 12:49 PM
    | Jun. 5, 2014, 12:49 PM | 2 Comments
  • Dec. 19, 2013, 5:38 PM
    | Dec. 19, 2013, 5:38 PM | Comment!
  • Nov. 27, 2013, 2:04 PM
    • BioReference Laboratories (BRLI -20.8%) plunges after providing Q4 and FY13 guidance.
    • "Despite continued strong volume growth, the Company believes there is an ongoing recalibration of reimbursement for the industry, which has resulted in substantial downward pressure from many payers regarding reimbursement," the company says, adding that it has "had to negotiate contract modifications to reimbursement rates, conditions of payment and / or eligibility with dozens of health plans representing a substantial numbers of lives nationwide."
    • Q4 patient volume seen at +15% Y/Y. Q4 revenue per patient for non-genetic test seen -4% versus Q3.
    • Q4 outlook: $0.40/share on revenue of $192M.
    • FY outlook: $1.65/share.
    • BLRI also says it "expects that guidance for 2014 will call for an increase in net revenues of 10%, an increase in patient volume of 10% and an increase in net income of 10%." (PR)
    | Nov. 27, 2013, 2:04 PM | Comment!
  • Nov. 27, 2013, 12:45 PM
    | Nov. 27, 2013, 12:45 PM | Comment!
  • Aug. 29, 2013, 11:18 AM
    • Bio-Reference Labs (BRLI +3%) moves up on a solid FQ3 earnings beat today.
    • Total revenue rose to $185,427, +16% from the same quarter last year and the highest recorded in a quarter in corporate history.
    • Net income increased by 17%.
    • Revenue per patient was $85.25, an increase of 7% over the $79.75 in the prior year.
    | Aug. 29, 2013, 11:18 AM | Comment!
  • Aug. 21, 2013, 3:42 PM
    • While correlation doesn't necessarily imply causation, it's probably worth noting that today's action in shares of Neogenomics (NEO -8.4%) mirrors the stock's dismal performance from last Tuesday.
    • The connection: Peer BioReference Laboratories (BRLI +2.5%) announced "strategic acquisitions" both today and on August 13.
    | Aug. 21, 2013, 3:42 PM | 3 Comments
  • Aug. 13, 2013, 3:15 PM
    • BioReference Laboratories (BRLI +2%) acquires most of Hunter Laboratories' assets, giving BRLI a West Cost presence and Medi-Cal in-network status.
    • "Having a local base for operations can provide significant operational and logistical synergies," CEO Marc Grodman notes. (PR)
    • Shares of Neogenomics (NEO -7.8%), a notable peer, are off sharply on the session.
    | Aug. 13, 2013, 3:15 PM | Comment!
  • Jul. 10, 2013, 12:55 PM
    More on William Blair's Bio-Reference (BRLI -8.8%) downgrade: A push for lower payment rates for lab tests could disproportionately hurt BRLI due to its exposure to blood-based cancer tests — rates for lymphoma tests could rise 70% or more, analysts say. Also moving on the news is Quest Diagnostics (DGX +1.4%) which William Blair thinks will be the least affected, while shares of Neogenomics (NEO -15.4%) plummet on above average volume.
    | Jul. 10, 2013, 12:55 PM | Comment!
  • Jul. 10, 2013, 12:45 PM
    Midday top 10 gainers: NEON +25%. INO +22%. NUS +15%. SKBI +14%. PCYC +13%. VRML +13%. BMJ +13%. MCP +13%. ADHD +11%. SPEX +11%.
    Midday top 10 Losers: ADVS -25%. NEO -17%. PME -14%. XNY -11%. CREG -11%. ALJ -9%. TRR -8%. RAX -8%. BRLI -8%. LCNB -8%.
    | Jul. 10, 2013, 12:45 PM | Comment!
  • Jul. 10, 2013, 12:16 PM
    Bio-Reference Laboratories (BRLI -8.1%) slips on a downgrade to Market Perform from Outperform at William Blair.
    | Jul. 10, 2013, 12:16 PM | Comment!
Visit Seeking Alpha's
BRLI vs. ETF Alternatives
Company Description
Bio-Reference Laboratories Inc is engaged in providing laboratory testing services. The Company offers chemical diagnostic tests including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis and toxicology.